title: Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.
authors.forename: Heleen D
authors.initials: HD
authors.lastname: de Koning
authors.forename: Joost
authors.initials: J
authors.lastname: Schalkwijk
authors.forename: Jos W M
authors.initials: JW
authors.lastname: van der Meer
authors.forename: Anna
authors.initials: A
authors.lastname: Simon
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D005260:Female; D056660:Hereditary Autoinflammatory Diseases / Q000188:drug therapy*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D053583:Interleukin-1beta / Q000378:metabolism*; D019873:Schnitzler Syndrome / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha